Yes and you replied with a simple comparison to what LDX's share price did post non-approval. What their share price did is completely irrelevant unless you provide some FA to go with it.
Let me ask a question then, why are you using LDX's share price movement post non-approval as a basis for what BOT's share will do? How are the fundamentals of each company post non-approval the same?
Ann: Botanix Partners with Telehealth Provider UpScriptHealth, page-25
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $572.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.0¢ | $1.366M | 4.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 342765 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 723414 | 18 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |